Navigation Links
Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer
Date:6/13/2010

Stemedica announced today the appointment of Lev Verkh, PhD as Chief Regulatory and Clinical Development Officer. Dr. Verkh will be responsible for managing all regulatory activities and clinical trials on behalf of the company.

(PRWEB) June 11, 2010 -- Stemedica Cell Technologies, Inc., a leader in adult stem cell research and manufacturing, announced today the appointment of Lev Verkh, PhD as Chief Regulatory and Clinical Development Officer. Dr. Verkh will be responsible for managing all regulatory activities and clinical trials on behalf of the company. "Dr. Verkh brings over twenty years of international regulatory and clinical trial experience to Stemedica," said Dr. Nikolai Tankovich, Stemedica's President & Chief Medical Officer. "We are confident that his contribution to our mission to bring innovative products to patients, following FDA guidelines, will be significant."

Dr. Verkh's clinical and regulatory experience includes working for Pfizer, Baxter Bio Sciences, the Alliance Pharmaceutical Corporation and the Alpha Therapeutic Corporation. He has directed national and multi-national Phase I, II, III and IV clinical trials in such areas as cardiology, oncology, peripheral artery disease, hematology, blood disorders and imaging methods. He is author or co-author of over 40 peer-reviewed publications. Through his efforts and the efforts of his teams, he has received FDA approval for several products that are currently on the market. "I am honored to be joining Stemedica's management team," said Dr. Verkh, "and am excited to work with the company's leading-edge stem cell technology."

In addition to directing Stemedica's clinical trials within the United States, Dr. Verkh will be assisting foreign regulatory agencies to establish guidelines for stem cell technologies in medicine. He will also assist in organizing and supervising clinical trials outside the United States utilizing Stemedica technology.

"With the rapid advancement of clinical application and development of adult stem cell technologies around the world, the addition of Dr. Verkh is essential to our long-term growth plan", said Maynard Howe, PhD, Stemedica's Chief Executive Officer. "Stemedica is working closely with government leaders, scientists and clinicians to establish and promote best scientific practices in the emerging field of stem cell research and therapy."

About Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies Inc. (www.stemedica.com) is a specialty biopharmaceutical company that is committed to the development and manufacturing of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and human stem cell clinical trials. The company is currently developing regulatory pathways for stroke and wound repair. Stemedica is headquartered in San Diego, California.

Media Contact for Stemedica: Dave McGuigan at dmcguigan (at) stemedica(dot)com

# # #

Read the full story at http://www.prweb.com/releases/stemedica-allogeneic/adult-stem-cells/prweb4122174.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Stemedica Completes Meeting with the FDA
2. United States Patent and Trademark Office Publishes Stemedica's Patent Application for the Treatment of Diabetic Retinopathy
3. The Jordanian Stem Cell Company Acquires Stem Cell Technology From Stemedica International S.A. - First Clinical Trail Anticipated To Begin Early 2010
4. Stemedica Achieves Major Milestone - Company Receives License to Manufacture Clinical Grade Stem Cells
5. Stemedica Selected By World Stem Cell Summit To Present Scientific Discoveries
6. Stemedica Requests Pre-IND Meeting With FDA
7. Stemedica Signs Scientific Advisory Board Agreement with Leading Pediatric Burn & Wound Care Researcher
8. Renowned Stem Cell Researcher Files Study Results With Stemedica
9. CIRM Completes Briefing Visit to Stemedica Cell Technologies
10. Stemedica Announces the Appointment of Dr. Michael Bayer as Director, Medical Services
11. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Stemedica Announces the Appointment of Dr. Lev Verkh as Chief Regulatory and Clinical Development Officer 
(Date:7/24/2017)... Intralytix, Inc. announced that it received $17.5 million in ... This investment marks the beginning of a close collaboration ... for various benefits in human health and in other ... As a global key player in yeasts ... for baking, food taste & pleasure, health care, and ...
(Date:7/24/2017)... FL (PRWEB) , ... July ... ... Strategic Analyst, Kenny Soulstring, today announced that the stock market news outlet ... in risk assessment diagnostic testing that screens and identifies exposure, progression and ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... leading radiology and imaging centers around the U.S. that offer MR Elastography for ... alternative to needle biopsy for staging liver fibrosis assessment. , “MRE:connect was ...
(Date:7/20/2017)... ... July 20, 2017 , ... Litmus Health ... announced its full advisory board. The board comprises leaders spanning business, technology, academia, ... PhD, former VP of Engineering, to Chief Technology Officer. Crooks will lead strategy ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 NXT-ID, Inc. (NASDAQ: ... company, announces the appointment of independent Directors Mr. Robin ... its Board of Directors, furthering the company,s corporate governance and ... Gino Pereira ... look forward to their guidance and benefiting from their considerable ...
(Date:4/4/2017)... 2017   EyeLock LLC , a leader of ... States Patent and Trademark Office (USPTO) has issued U.S. ... of an iris image with a face image acquired ... company,s 45 th issued patent. ... given the multi-modal biometric capabilities that have recently come ...
(Date:3/29/2017)... March 29, 2017  higi, the health IT company ... North America , today announced a Series ... acquisition of EveryMove. The new investment and acquisition accelerates ... tools to transform population health activities through the collection ... higi collects and secures data today on ...
Breaking Biology News(10 mins):